Estradiol acutely inhibits whole body lipid oxidation and attenuates lipolysis in subcutaneous adipose tissue: a randomized, placebo-controlled study in postmenopausal women.

@article{Gormsen2012EstradiolAI,
  title={Estradiol acutely inhibits whole body lipid oxidation and attenuates lipolysis in subcutaneous adipose tissue: a randomized, placebo-controlled study in postmenopausal women.},
  author={Lars Christian Gormsen and Christian H{\o}st and Britta E. Hjerrild and Steen B{\o}nl{\o}kke Pedersen and S{\o}ren Nielsen and Jens Sandahl Christiansen and Claus H{\o}jbjerg Gravholt},
  journal={European journal of endocrinology},
  year={2012},
  volume={167 4},
  pages={
          543-51
        }
}
CONTEXT Estradiol (E(2)) promotes and maintains the female phenotype characterized by subcutaneous fat accumulation. There is evidence to suggest that this effect is due to increased anti-lipolytic α2A-adrenergic receptors, but whether this requires long-term exposure to E(2) or is an immediate effect is not clear. OBJECTIVE To study acute effects of a single dose (4 mg) of 17β-E(2) on regional and systemic lipolysis. METHODS Sixteen postmenopausal women (age, 595 years; weight, 6710 kg… 

Figures from this paper

Estradiol does not directly regulate adipose lipolysis

The results indicate that E2 does not directly regulate adipose tissue lipolysis and CL increased FFA and glycerol accumulation in the media as well as HSL phosphorylation by several fold in r.p. and iWAT explants.

Estrogen and body weight regulation in women: the role of estrogen receptor alpha (ER-α) on adipocyte lipolysis.

It is suggested that the effect of estrogen to reduction of lipolysis was through activation of estrogen receptor alpha (ER-α) in adipose tissue.

Effect of conjugated estrogens and bazedoxifene on glucose, energy and lipid metabolism in obese postmenopausal women.

A short treatment of obese postmenopausal women with CE/BZA does not alter insulin action or ectopic fat but increases serum markers of hepatic de novo lipogenesis and TAG production.

Adrenergic control of lipolysis in women compared with men.

The hypothesis that the greater rate of lipolysis in women with infusion of E was likely due to lesser α2 antilipolytic activation may help explain why women have greater lipolytic action and fat oxidation during exercise, a time when epinephrine concentration is elevated.

Tissue-specific effects of estrogen on glycerol channel aquaporin 7 expression in an ovariectomized mouse model of menopause

  • B. JinX. Chen J. Shu
  • Biology
    Climacteric : the journal of the International Menopause Society
  • 2017
The results suggest that estrogen has tissue-specific effects on AQP7 expression, and modulation of AQP 7 by estrogen alters the balance of adipocyte metabolism between adipose tissue depots.

Estrogen modulates metabolic risk profile after resistance training in early postmenopausal women: a randomized controlled trial.

Use of transdermal ET reduced adipose tissue loss, but improved metabolic blood markers when combined with 12 weeks of progressive resistance training in early postmenopausal women.

Lipedema and the Potential Role of Estrogen in Excessive Adipose Tissue Accumulation

Estrogen, a key regulator of adipocyte lipid and glucose metabolism, and female-associated body fat distribution are postulated to play a contributory role in the pathophysiology of lipedema.

Selective adipocyte loss of Angiopoietin-2 prompts female-specific obesity and metabolic syndrome

Sex Differences in Body Fat Distribution

A relatively high adipose tissue glucocorticoid reactivation by 11β-hydroxysteroid dehydrogenase type 1 appears to promote specific accumulation of visceral fat and to alter adipocyte function in humans.

Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes

The role of estrogens and their receptors on the central regulation of caloric expenditure and the influence they exert on the differentiation and function of adipocytes are discussed.

References

SHOWING 1-10 OF 44 REFERENCES

Acute estrogen exposure does not affect basal very low-density lipoprotein-triglyceride production or oxidation in postmenopausal women.

It is proposed that HRT-associated dyslipidemia has a gradual rather than immediate onset and short-term E(2) elevation does not affect VLDL-TG production, oxidation, or clearance in humans.

Estradiol may limit lipid oxidation via Cpt 1 expression and hormonal mechanisms.

It is suggested that, although E(2) is likely to suppress lipid oxidation and promote TG synthesis, these effects are not manifested in a relative increase in carcass adiposity after 18 days of treatment, at least under conditions of negative energy balance.

The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women.

The suppression of lipidox during oral estrogen therapy may increase fat mass although the fall in IGF-I may lead to a loss of lean body mass, and the route-dependent changes in body composition observed during estrogen replacement therapy may have important implications for postmenopausal health.

Regional adipose tissue metabolism in postmenopausal women after treatment with exogenous sex steroids.

The findings indicate, therefore, that EE in doses used in oral contraception might promote lipid accumulation in the femoral adipose tissue depot.

Estrogen controls lipolysis by up-regulating alpha2A-adrenergic receptors directly in human adipose tissue through the estrogen receptor alpha. Implications for the female fat distribution.

It is demonstrated that estrogen attenuates the lipolytic response through up-regulation of the number of antilipolytic alpha2A-adrenergic receptors only in sc and not in visceral fat depots, which offers an explanation how estrogen maintains the typical female sc fat distribution because estrogen seems to inhibit lipolysis only inSc depots and thereby shifts the assimilation of fat from intraabdominal depots to sc depots.

Human fat cell lipolysis: biochemistry, regulation and clinical role.

  • P. Arner
  • Biology, Medicine
    Best practice & research. Clinical endocrinology & metabolism
  • 2005

Intravenous estrogens increase insulin clearance and action in postmenopausal women.

It is suggested that acute CE administration increases insulin clearance and action in postmenopausal women and reduces insulin action in women not using hormone replacement.

Activation of alpha2-adrenergic receptors blunts epinephrine-induced lipolysis in subcutaneous adipose tissue during a hyperinsulinemic euglycemic clamp in men.

In situ, insulin counteracts the epinephrine-induced lipolysis in adipose tissue and involves 1) reduction of lipolytic stimulation mediated by the beta-adrenergic pathway and 2) the antilipolytic component of epinphrine action mediated by alpha2-ARs.